Speaker

Patrick is an established pharmaceutical executive and practitioner with proven leadership in proactive risk identification, deployment of strategies to enhance compliance controls, and implementation of detection systems to eliminate blind spots. He is skilled in policy deployment, Computer System Validation, Data Integrity/Governance, Risk Management, Supply Chain Logistics and application of AI for the next generation of quality professionals. He has trained FDA field inspectors for facility inspection techniques and has delivered talks on deployment of risk strategies and modern signal detection. His expertise also includes outsourcing and integrating efficient governance of Facilities Management and laboratory services across US/UK and Asia-Pacific. Pat’s frequent blogs and articles help educate the industry become aware of emerging global risks, technologies, and their effect on the global supply chain.

Pandy Song joined Northern Light Venture Capital (NLVC) in 2016 and brought with him a profound understanding of China’s pharmaceutical industry. he was extensive experience in corporate strategic planning and implementation, along with a background in clinical trial applications, business development, team building, and marketing management. His primary areas of focus at NLVC are biotech and biopharmaceuticals, with notable investments including SHIP, Zelgene, Belief Biomed, Genfleet, Sanegenebio and NGGT

Prior to NLVC, Pandy worked in the Department of Strategic Research at Staidson Biopharmaceutical Co., Ltd., where he handled business development work surrounding global licensing and strategic alliance management, including joint ventures, partnerships, and value-add collaborations, Additionally, he led market marketplace assessments of China’s pharmaceutical industry, including policy work and trend identification, before ultimately helping develop the company’s long-term strategy and dynamic modeling processes.

Pandy holds a PhD in Biophysics from the Chinese Academy of Medical Sciences, a PhD in Philosophy from Peking Union Medical College, and DBA (doctor business administration) degree from Hong Kong University and Peking University

Dr. Laurent Metz is a global healthcare leader with over 30 years of experience in medical devices, pharmaceuticals, and vaccines, spanning the full product lifecycle from early discovery to post-launch. His expertise includes health economics, market access, medical affairs, commercial strategy, and scaling up organizations to achieve sustainable growth.
He spent 28 years at Johnson & Johnson in senior leadership roles across Europe, the United States, Latin America, Africa, and a decade in Asia-Pacific. In Singapore, he established the Market Access Center of Excellence for Medical Devices, leading regional teams and pioneering value-based healthcare initiatives with policymakers, providers, and academic institutions. Later, as Global Market Access & Policy Head for Johnson & Johnson Global Public Health, he advanced access strategies for breakthrough technologies in underserved markets, including vaccines and treatments for infectious diseases.

Dr. Metz has also served as Chief Medical Officer for Wandercraft, guiding clinical, access, regulatory, and commercial strategies for advanced robotic exoskeletons in the U.S. market. He is a Partner at Robin Hood Ventures, an active early-stage investor group in healthcare, life sciences, and technology, and serves on the Board of StarkAge, a biotech company specializing in oncology and senescence cell-targeted therapies.
His career reflects a commitment to building bridges across markets, fostering innovation, and improving global patient access to transformative healthcare solutions.

Prof. Tao Deng is a faculty member at the Institute of Microbiology, Chinese Academy of Sciences, and obtained her PhD from Oxford University. Her research primarily focuses on the mechanisms by which the core replication machinery of influenza viruses, the viral ribonucleoprotein complexes (vRNPs), functions within host cells, as well as the mechanisms underlying their selective packaging. As corresponding author, she has published a series of original papers in journals such as Nucleic Acids Research, Nature Communications, Cell Reports, EMBO Reports, and Journal of Virology, making significant contributions to advancing our understanding of the detailed molecular mechanism of influenza virus replication. She has also led a major national project on infectious disease prevention and control as the principal investigator and is currently leading a national key R&D project, in addition to having hosted several projects funded by the National Natural Science Foundation of China.

Dr. Hui Tian is the founder and CEO of Axbio, a global leader in integrated circuit biotechnology. Axbio is developing a next-generation electrochemical detection platform to transform the life sciences tools and diagnostics industry.
Dr. Tian is a leading scientist who is the inventor of over 100 granted patents globally, with extensive leadership in biotechnology. Before founding Axbio, Dr. Tian was Vice President at a California-based company which develops genetic analysis platform designed for real-time DNA sequencing, and later continued as Vice President at the sequencing division of a global pharmaceutical company until 2016. Dr. Tian also served leadership roles at Silicon Valley technology companies, including vice president at InVisage Technologies Inc., director at Pixim, Inc., and principal sensor scientist of IC Media Corporation. He received his PhD & MS from Stanford University and MS & BS from Tsinghua University (China).

Holly Meng serves as the Co-founder and Chief Executive Officer of EXIN BioPharma, bringing with her an extensive background of over three decades in business, industry, finance, international trade, higher education, and nonprofit operations. As a seasoned entrepreneur, she has successfully established and exited multiple businesses in her native Hong Kong and her current residence of 25 years in Philadelphia, Pennsylvania. In her capacity as a Senior Specialist of Business with SBA certification at the Fox School, Holly has provided invaluable guidance to more than 50 startups and small-to-medium enterprises (SMEs) in areas such as business planning and operations, funding and investment, marketing, business development, finance, and budgeting. Over the past decade, she has also made significant contributions as the Program Creator and Director of Temple Office of Executive Leadership Education, establishing extensive cross-border networking connections with over a thousand visiting executives, domestic leaders, and organizations on both national and global levels.

Holly has been an active volunteer in numerous nonprofit organizations, holding positions such as President of the American Center for Asian Students, Deputy Curator of the American Chinese Museum, and Vice President of Chinese BioPharmaceutical Association of Greater Philadelphia. In recognition of her exceptional achievements, she was awarded the U.S. President’s Lifetime Achievement Award in 2022. Currently, Holly is pursuing her doctorate in Higher Education Leadership and Policy.

Dr. Tan Yu Yan, Chief Physician in the Department of Neurology at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Managing Editor of Translational Neurodegeneration journal. Her primary research focus is on the innovative diagnosis and treatment as well as the pathogenesis of neurodegenerative diseases such as Parkinson’s disease and multiple system atrophy. From 2014 to 2016, she worked as a visiting scholar at the University of Arizona, studying the role of epigenetics in the pathogenesis of Parkinson’s disease and Alzheimer’s disease.

In recent years, she has paid particular attention to the diagnostic and differential diagnostic roles of gut microbiota and metabolic products, as well as invasive and non-invasive neuromodulation of Parkinson’s disease and multiple system atrophy.

Jiawei Tang is the Co-founder and COO of Global Biopharma Partnerships. She holds a Master’s degree in Digital Transformation in Healthcare Management and brings over 15 years of extensive experience in the healthcare and life sciences industry, with a proven track record in sales,
corporate strategy, and marketing.

Her professional background includes 12 years in management roles at Pfizer, a global pharmaceutical leader, and one year as Commercial Strategy Director at Resolian, a renowned contract research organization (CRO). She has successfully led and implemented numerous brand transformation, corporate strategy, integrated marketing communications, and business innovation projects across major markets, including the United States, the United Kingdom, Australia, and China.

In addition to her professional work, Jiawei serves in volunteer leadership roles at several nonprofit healthcare organizations, including as a Geographic Expansion Leadership Member at the Healthcare Business Association, as an Advisory Borad member of One Patient One cure and as Vice President of the Chinese Biopharmaceutical Association Greater Philadelphia.

Bob Rovinsky serves as Associate Director of Operations at B+labs, where he plays a central role in delivering on the organization’s mission to accelerate the success of early-stage life science companies. Since joining B+labs in 2021, in addition to being a primary participant of the startup of the life science incubator, Bob has been instrumental in building a safe, efficient, and fully compliant operational environment that enables scientists and entrepreneurs to focus on innovation and successful outcomes.Drawing on over 36 years of experience in facility design, commissioning, operations, environmental health and safety (EHS), sustainability, and regulatory/quality compliance, Bob develops and oversees operational systems that keep B+labs’ shared laboratory and office spaces running seamlessly. His expertise ensures that startups have access to fully functional, BSL-2 compliant laboratories, well-maintained equipment, and robust safety programs—critical foundations for breakthrough research in biotechnology and pharmaceuticals.Before B+labs, Bob held leadership positions in academia, private industry and public institutions, including Takeda, Sun Pharma, Axalta, Airborne Systems, Frontida BioPharm, URL Pharma, The Wistar Institute and the University of Pennsylvania, as well as service in the U.S. Air Force as a Bioenvironmental Engineer. Across these roles, he has consistently championed operational excellence, risk management, and sustainability. His work at B+labs reflects his commitment to creating a safe, sustainable, and high-performance environment where life science ventures can thrive and deliver transformative health solutions.
Bob holds a Master of Environmental Studies from the University of Pennsylvania with an emphasis in Policy and Risk Management and a Bachelor of Science in. Environmental Engineering from Temple University, along with specialized training from the U.S. Air Force School of Aerospace Medicine.

Dr. Rose Ritts, PhD is a Managing Partner of the Black Opus Special Situations Group (BOSS) Fund and the Black Venture Capital Consortium (BVCC) Fund, focused on early-stage investments into Emerging Technology companies. She has 35 years of experience as an investor, founder, and leader and has helped launch dozens of startups across biotech, healthcare and deeptech, with 28 achieving exits over $150mm, including 3 over $1B; and $400mm+ of monetized IP. Prior to joining BOSS and BVCC, Dr. Ritts spent 18 years as a Chief Innovation Officer at US universities and academic health centers, first in North Carolina at Duke University & Duke Health, and then in Philadelphia at Jefferson Health & Thomas Jefferson University. She served in the US Federal Government as a Program Manager at DARPA, in the Department of Defense, where she managed programs in MicroFluidic Systems and Cellular Computing and served as a member of government think tanks and proposal review panels across multiple government agencies. Dr. Ritts received her undergraduate degree from Duke University and earned both her PhD and MS degrees from Stanford University.